Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18–25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016

Welby, Sarah; Rosillon, Dominique; Feng, Yang; Borys, Dorota

doi:10.1080/14760584.2022.2021077

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the four trials included in the study, the highly sensitive HPV genotyping assay SPF10‐LiPA25 25 was used to detect the presence of a type‐specific HPV infection. Besides, a strict criterion to define natural clearance, requiring at least two consecutive negative samples for the same HPV type, was adopted in the analysis 9 . These measures should help alleviate, although not eliminate, the potential interference of redetection/reactivation.…”

Section: Discussionmentioning

confidence: 99%

“…Besides, a strict criterion to define natural clearance, requiring at least two consecutive negative samples for the same HPV type, was adopted in analysis. 9 These measures should help alleviate, although not eliminate, the potential interference of redetection/reactivation. Rather, it is quite possible that the new infections analyzed in our study also include "reinfections" to the HPV types infected and naturally cleared before baseline.…”

Section: Immunogenicitymentioning

confidence: 99%

“…8 Females with existing HPV infections remain at risk of persistent infections, subsequent multiple infections (i.e., new infections of other HPV types), and recurrent infections. 9,10 Previous evidence has confirmed that HPV vaccination does not accelerate the clearance of existing HPV but might reduce the risk of cervical intraepithelial neoplasia (CIN) after excision treatment. 7,11,12 However, vaccine protection remains incompletely defined against new infections or recurrent infections following natural clearance.…”

Section: Introductionmentioning

confidence: 99%

“…As demonstrated in multinational data, 62% of the sexually active females were tested to be HPV‐DNA‐positive within 3 years after sexual debut 8 . Females with existing HPV infections remain at risk of persistent infections, subsequent multiple infections (i.e., new infections of other HPV types), and recurrent infections 9,10 . Previous evidence has confirmed that HPV vaccination does not accelerate the clearance of existing HPV but might reduce the risk of cervical intraepithelial neoplasia (CIN) after excision treatment 7,11,12 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and immunogenicity of AS04‐HPV‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide

Wen,

Xu,

Zhao

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Females with existing high‐risk HPV (HR‐HPV) infections remain at risk of subsequent multiple or recurrent infections, on which benefit from HPV vaccines was under‐reported. We pooled individual‐level data from four large‐scale, RCTs of AS04‐HPV‐16/18 vaccine to evaluate efficacy and immunogenicity in females DNA‐positive to any HR‐HPV types at first vaccination. Females receiving the AS04‐HPV‐16/18 vaccine in the original RCTs constituted the vaccine group in the present study, while those unvaccinated served as the control group. Vaccine efficacy (VE) against new infections and associated cervical intraepithelial neoplasia (CIN) 2+ in females DNA‐negative to the considered HR‐HPV type but positive to any other HR‐HPV types, VE against reinfections in females DNA‐positive to the considered HR‐HPV type but cleared naturally during later follow‐up, and levels of anti‐HPV‐16/18 IgG were assessed. Our final analyses included 5137 females (vaccine group = 2532, control group = 2605). The median follow‐up time was 47.88 months (IQR: 45.72‐50.04). For the prevention of precancerous lesions related to the non‐infected HR‐HPV types at baseline, VE against HPV‐16/18 related CIN 2+ was 82.70% (95% CI: 63.70‐93.00%). For the prevention of reinfections related to the infected HR‐HPV types following natural clearance, VE against HPV‐16/18 12MPI was non‐significant (p > .05), albeit robust immunity persisted for at least 48 months. Females with existing HR‐HPV infections at first vaccination still benefit from vaccination in preventing precancers related to the non‐infected types at baseline. VE against reinfections related to the infected types following natural clearance remains to be further investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Immunogenicitymentioning

confidence: 99%